146 related articles for article (PubMed ID: 17822280)
1. Formaldehyde-releasing prodrugs in combination with adriamycin can overcome cellular drug resistance.
Cutts SM; Nudelman A; Pillay V; Spencer DM; Levovich I; Rephaeli A; Phillips DR
Oncol Res; 2005; 15(4):199-213. PubMed ID: 17822280
[TBL] [Abstract][Full Text] [Related]
2. Molecular basis for the synergistic interaction of adriamycin with the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate (AN-9).
Cutts SM; Rephaeli A; Nudelman A; Hmelnitsky I; Phillips DR
Cancer Res; 2001 Nov; 61(22):8194-202. PubMed ID: 11719450
[TBL] [Abstract][Full Text] [Related]
3. Activation of clinically used anthracyclines by the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate.
Cutts SM; Swift LP; Pillay V; Forrest RA; Nudelman A; Rephaeli A; Phillips DR
Mol Cancer Ther; 2007 Apr; 6(4):1450-9. PubMed ID: 17431124
[TBL] [Abstract][Full Text] [Related]
4. The role of intracellularly released formaldehyde and butyric acid in the anticancer activity of acyloxyalkyl esters.
Nudelman A; Levovich I; Cutts SM; Phillips DR; Rephaeli A
J Med Chem; 2005 Feb; 48(4):1042-54. PubMed ID: 15715472
[TBL] [Abstract][Full Text] [Related]
5. Formation of mitoxantrone adducts in human tumor cells: potentiation by AN-9 and DNA methylation.
Parker BS; Rephaeli A; Nudelman A; Phillips DR; Cutts SM
Oncol Res; 2004; 14(6):279-90. PubMed ID: 15206490
[TBL] [Abstract][Full Text] [Related]
6. Mode of interaction between butyroyloxymethyl-diethyl phosphate (AN-7) and doxorubicin in MCF-7 and resistant MCF-7/Dx cell lines.
Engel D; Nudelman A; Levovich I; Gruss-Fischer T; Entin-Meer M; Phillips DR; Cutts SM; Rephaeli A
J Cancer Res Clin Oncol; 2006 Oct; 132(10):673-83. PubMed ID: 16826403
[TBL] [Abstract][Full Text] [Related]
7. Sequence specificity of adriamycin-DNA adducts in human tumor cells.
Cutts SM; Swift LP; Rephaeli A; Nudelman A; Phillips DR
Mol Cancer Ther; 2003 Jul; 2(7):661-70. PubMed ID: 12883039
[TBL] [Abstract][Full Text] [Related]
8. The cardio-protecting agent and topoisomerase II catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated cytotoxicity.
Swift LP; Cutts SM; Nudelman A; Levovich I; Rephaeli A; Phillips DR
Cancer Chemother Pharmacol; 2008 Apr; 61(5):739-49. PubMed ID: 17594094
[TBL] [Abstract][Full Text] [Related]
9. Correlation of in Situ Oxazolidine Formation with Highly Synergistic Cytotoxicity and DNA Cross-Linking in Cancer Cells from Combinations of Doxorubicin and Formaldehyde.
Barthel BL; Mooz EL; Wiener LE; Koch GG; Koch TH
J Med Chem; 2016 Mar; 59(5):2205-21. PubMed ID: 26881291
[TBL] [Abstract][Full Text] [Related]
10. Potential Therapeutic Advantages of Doxorubicin when Activated by Formaldehyde to Function as a DNA Adduct-Forming Agent.
Cutts SM; Rephaeli A; Nudelman A; Ugarenko M; Phillips DR
Curr Top Med Chem; 2015; 15(14):1409-22. PubMed ID: 25866273
[TBL] [Abstract][Full Text] [Related]
11. An evaluation of the interaction of pixantrone with formaldehyde-releasing drugs in cancer cells.
Mansour OC; Nudelman A; Rephaeli A; Phillips DR; Cutts SM; Evison BJ
Cancer Chemother Pharmacol; 2022 Jun; 89(6):773-784. PubMed ID: 35460360
[TBL] [Abstract][Full Text] [Related]
12. Activation of adriamycin by the pH-dependent formaldehyde-releasing prodrug hexamethylenetetramine.
Swift LP; Cutts SM; Rephaeli A; Nudelman A; Phillips DR
Mol Cancer Ther; 2003 Feb; 2(2):189-98. PubMed ID: 12589036
[TBL] [Abstract][Full Text] [Related]
13. The power and potential of doxorubicin-DNA adducts.
Cutts SM; Nudelman A; Rephaeli A; Phillips DR
IUBMB Life; 2005 Feb; 57(2):73-81. PubMed ID: 16036566
[TBL] [Abstract][Full Text] [Related]
14. ABT-737 overcomes Bcl-2 mediated resistance to doxorubicin-DNA adducts.
Ugarenko M; Nudelman A; Rephaeli A; Kimura K; Phillips DR; Cutts SM
Biochem Pharmacol; 2010 Feb; 79(3):339-49. PubMed ID: 19737541
[TBL] [Abstract][Full Text] [Related]
15. Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death.
Swift LP; Rephaeli A; Nudelman A; Phillips DR; Cutts SM
Cancer Res; 2006 May; 66(9):4863-71. PubMed ID: 16651442
[TBL] [Abstract][Full Text] [Related]
16. Formaldehyde-releasing prodrugs specifically affect cancer cells by depletion of intracellular glutathione and augmentation of reactive oxygen species.
Levovich I; Nudelman A; Berkovitch G; Swift LP; Cutts SM; Phillips DR; Rephaeli A
Cancer Chemother Pharmacol; 2008 Aug; 62(3):471-82. PubMed ID: 18030472
[TBL] [Abstract][Full Text] [Related]
17. Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
Engel D; Nudelman A; Tarasenko N; Levovich I; Makarovsky I; Sochotnikov S; Tarasenko I; Rephaeli A
J Med Chem; 2008 Jan; 51(2):314-23. PubMed ID: 18163551
[TBL] [Abstract][Full Text] [Related]
18. Anticancer prodrugs of butyric acid and formaldehyde protect against doxorubicin-induced cardiotoxicity.
Rephaeli A; Waks-Yona S; Nudelman A; Tarasenko I; Tarasenko N; Phillips DR; Cutts SM; Kessler-Icekson G
Br J Cancer; 2007 Jun; 96(11):1667-74. PubMed ID: 17473824
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in understanding and exploiting the activation of anthracyclines by formaldehyde.
Cutts SM; Swift LP; Rephaeli A; Nudelman A; Phillips DR
Curr Med Chem Anticancer Agents; 2005 Sep; 5(5):431-47. PubMed ID: 16178771
[TBL] [Abstract][Full Text] [Related]
20. Zosuquidar and an albumin-binding prodrug of zosuquidar reverse multidrug resistance in breast cancer cells of doxorubicin and an albumin-binding prodrug of doxorubicin.
Abu Ajaj K; Graeser R; Kratz F
Breast Cancer Res Treat; 2012 Jul; 134(1):117-29. PubMed ID: 22228402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
